Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection

Over the last several years, many advances have been made in the treatment of chronic hepatitis C virus (HCV) infection with the development of direct-acting antivirals. Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boos...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Michael A, Lim, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654544/
https://www.ncbi.nlm.nih.gov/pubmed/26622169
http://dx.doi.org/10.2147/DDDT.S80226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654544/
https://www.ncbi.nlm.nih.gov/pubmed/26622169
http://dx.doi.org/10.2147/DDDT.S80226

Ejemplares similares